NCT07511036 2026-04-06
PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
Clinical Trials
6 trialsNCT07510334 2026-04-03
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Mayo Clinic
Phase 2 Not yet recruiting
NCT07403877 2026-02-11
TORCH-OPTIMA
Fudan University
Phase 2 Not yet recruiting
NCT07355205 2026-01-21
FLINN
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT05597800 2022-10-28
LUNGVIR
Universita di Verona
Phase 2 Not yet recruiting
NCT02498756 2015-07-15
Cytokine-induced Killer Study for Patients With Stage II Melanoma
The First People's Hospital of Changzhou
Phase 2 Not yet recruiting